IQVIA Global Trends in R&D 2024 Report

IQVIA has published a report "Global Trends in R&D 2024" exploring current developments and prospects in pharmaceutical research and development. The report evaluates trends in drug launches and clinical trials, examining R&D funding and company activities. It also highlights the innovation ecosystem's growth, focusing on factors like reduced trial durations and changes in 'white space' in development timelines, which vary across diseases.

Biomedical advances are transforming healthcare globally. The multi-stakeholder ecosystem that enables this progress has been buffeted by the global COVID-19 pandemic and is resetting and refocusing on future opportunities to advance the understanding of human biology and disease, discover and develop new therapeutics, and provide evidence of the clinical value of these innovations — for individual patients, populations, and health systems. By all of the traditional metrics, including funding levels, numbers of trial starts, drug launches, R&D success rates, and many others, it is clear that industry and investors continue to see tremendous value in the vast array of ongoing research programs around the world.

This report assesses the trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The results of research are compared to the input effort in a Clinical Development Productivity Index. The notable acceleration and adaptability of the innovation ecosystem is examined in terms of several enablers of R&D productivity, including the relationship between shortening trial durations and the ‘white space’ within clinical development timelines that have been reducing for some diseases and increasing for others.

For more, please find the original story source here.